Monitor the ASCO poster for signs of clinical activity and tolerability in solid tumors, particularly in platinum-resistant ovarian cancer, which could influence future development plans and partnership interest. Lack of data in this release limits immediate trading implications.
Price Chart
Executive Summary
NextCure announced that Phase 1 data for SIM0505, an investigational antibody-drug conjugate targeting CDH6 in solid tumors, will be presented at ASCO 2026. The poster presentation represents a clinical milestone for the program but does not include new efficacy or safety data.
Key Facts
- Phase 1 data for SIM0505 to be presented at ASCO 2026 in a poster session on June 1, 2026.
- SIM0505 is an anti-CDH6 antibody-drug conjugate with a proprietary TOPOi payload, being evaluated in advanced solid tumors including platinum-resistant ovarian cancer.
- NextCure holds global rights to SIM0505 except in China, Hong Kong, Macau, and Taiwan, which are retained by Simcere Zaiming.
- No clinical results or financial figures were disclosed in the press release.
Financial Impact
No direct financial impact disclosed; presentation may provide clinical validation and de-risk the asset modestly.
Risk Factors
- Phase 1 data may show limited efficacy or safety concerns, limiting further development.
- NextCure remains pre-revenue with a history of losses and dependence on external financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278150 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.22 (−3.95%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.22 (+22.36%) |
Aug 4, 2026 12w ago | 425 | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.22 (+3.88%) |
Jul 14, 2026 15w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.22 (−20.59%) |
Jul 14, 2026 15w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.22 (+20.59%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.22 (+54.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers